Skip to main content
ACCUEIL
À PROPOS
À PROPOS DE CDP NETWORK
Nos mission & vision
Notre objet
Gouvernance
Conformité
Microsites
CPD
Membres
COORDONNÉES
Connexion
Experts
ACCUEIL
À PROPOS
À PROPOS DE CDP NETWORK
Nos mission & vision
Notre objet
Gouvernance
Conformité
Microsites
CPD
Membres
COORDONNÉES
Connexion
Experts
Accueil
Microsites
Évolution DT2
FR
EN
Ressources du programme
Jeu de diapositives du programme
Tournée de conférenciers
Voir en ligne
|
Télécharger
Jeu de diapositives du programme
Événements régionaux
Voir en ligne
|
Télécharger
Bibliographie du programme
Télécharger
Déclaration d’intérêts des conférenciers et des modérateurs
Progrès qui change la donne dans la prise en charge du DT2 : un aperçu
1. Milestones in the history of diabetes mellitus: The main contributors - Marianna Karamanou et al. (Nature Reviews Endocrinology 2021)
Données probantes qui changent la donne : iSGLT-2 et les agonistes des récepteurs du GLP-1
1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes - Zinman B, et al. (N Engl J Med. 2015)
2. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes - Marso S, et al. (N Engl J Med. 2016)
3. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes - Marso S, et al. (N Engl J Med. 2016)
4. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes - Neal B, et al. (N Engl J Med. 2017)
5. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy - Perkovic V, et al. (N Engl J Med. 2019)
6. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial - Gerstein HC, et al. (Lancet. 2019)
7. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes - Wiviott SD, et al. (N Engl J Med. 2019)
8. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction - McMurray JJ, et al. (N Engl J Med. 2019)
9. Dapagliflozin in Patients with Chronic Kidney Disease - Heerspink HJL, et al. (N Engl J Med. 2020)
10. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure - Packer M, et al. (N Engl J Med. 2020)
11. Empagliflozin in Heart Failure with a Preserved Ejection Fraction - Anker SD, et al. (N Engl J Med 2021)
12. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction - Solomon SD, et al. (N Engl J Med. 2022)
13. Empagliflozin in Patients with Chronic Kidney Disease - The EMPA-KIDNEY Collaborative Group (N Engl J Med. 2023)
Progrès qui change la donne dans les traitements à base d’incrétines : double agonisme des récepteurs du GIP/GLP-1
1. The expanding incretin universe: from basic biology to clinical translation – Drucker D, et al. (Diabetologia 2023)
2. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (Rosenstock et al, Lancet. 2021)
3. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes - Frías JP, et al. (N Engl J Med. 2021)
4. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial (Ludvik et al, Lancet 2021)
5. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial (Del Prato et al, Lancet 2021)
6. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial (Dahl et al, JAMA 2022)
Affiner les priorités dans la prise en charge du DT2 : lignes directrices et recommandations qui changent la donne
1. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update - Lipscombe L, et al. (Can J Diabetes 2020)
2. Blood Glucose Monitoring in Adults and Children with Diabetes: Update 2021 - Cheng AYY, et al. (Can J Diabetes 2021)
3. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
4. Remission of Type 2 Diabetes: Diabetes Canada Clinical Practice Guidelines Expert Working Group - Mackay D, et al. (Can J Diabetes 2022)
Sortie
cpdisup
